Clinical trial
A Randomized, Double-Masked, Vehicle-Controlled Crossover Clinical Trial to Assess Efficacy and Safety of 0.25% Reproxalap Ophthalmic Solution Compared to Vehicle in Subjects With Dry Eye Disease
NCT05424549 is registered in ClinicalTrials.gov with Aldeyra Therapeutics, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-Masked, Vehicle-Controlled Crossover Clinical Trial to Assess Efficacy and Safety of 0.25% Reproxalap Ophthalmic Solution Compared to Vehicle in Subjects With Dry Eye Disease
- Lead sponsor
- Aldeyra Therapeutics, Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- March 9, 2022
- Completion date
- May 9, 2022
- Enrollment
- 63 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.